Article Information
PubMed
Published By
Print ISSN
Online ISSN
History
- Published online August 15, 2019.
Article Versions
- Latest version (April 15, 2019 - 04:00).
- You are currently viewing a Latest version of this article (August 15, 2019 - 04:00).
- View the most recent version of this article
Copyright & Usage
© 2019 The Journal of Rheumatology
Author Information
- Michael Antony Bowes,
- Gwenael Alain Guillard,
- Graham Richard Vincent,
- Alan Donald Brett,
- Christopher Brian Hartley Wolstenholme and
- Philip Gerard Conaghan
- From Imorphics Ltd., Manchester; Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and National Institute for Health Research (NIHR) Leeds Biomedical Research Centre, Leeds, UK.
This study was supported by internal funding. Scientific and financial support for the US Foundation for the National Institutes of Health (FNIH) Osteoarthritis Biomarkers Consortium and the study are made possible through grants and direct contributions provided by AbbVie, Amgen, Arthritis Foundation, Bioiberica S.A., DePuy Mitek, Flexion Therapeutics, GlaxoSmithKline, Merck Serono, Rottapharm Madaus, Sanofi, and Stryker, The Pivotal Osteoarthritis Initiative (OAI) Magnetic Resonance Imaging Analyses (POMA) Study, NIH HHSN2682010000. The OAI is a public–private partnership comprising 5 contracts (N01-AR-2-2258; N01-AR-2-2259; N01-AR-2-2260; N01-AR-2-2261; N01-AR-2-2262) funded by the NIH, a branch of the Department of Health and Human Services, and conducted by the OAI Study Investigators. Funding partners include Merck Research Laboratories, Novartis Pharmaceuticals Corp., GlaxoSmithKline, and Pfizer Inc. Private sector funding for the Consortium and OAI is managed by the FNIH. This manuscript was prepared using an OAI public use dataset and does not necessarily reflect the opinions or views of the OAI investigators, the NIH, or the private funding partners. PGC is supported in part by the NIHR infrastructure at Leeds. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR, or the Department of Health.
PGC has undertaken consultancies or speaker bureaus for AbbVie, Flexion, Novartis, and Pfizer. MAB, GAG, GRV, CBW, and ADB are employees of Imorphics Ltd., a wholly owned subsidiary of Stryker Corp. M.A. Bowes, PhD, Imorphics Ltd.; G.A. Guillard, PhD, Imorphics Ltd.; G.R. Vincent, PhD, Imorphics Ltd.; A.D. Brett, PhD, Imorphics Ltd.; C.B. Wolstenholme, BSc, Imorphics Ltd.; P.G. Conaghan, MBBS, PhD, FRACP, FRCP, Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds and NIHR Leeds Biomedical Research Centre. Address correspondence to Prof. P.G. Conaghan, Leeds Institute of Rheumatic and Musculoskeletal Medicine, Chapel Allerton Hospital, Chapeltown Road, Leeds LS7 4SA, UK. E-mail: p.conaghan@leeds.ac.uk.
Accepted for publication March 26, 2019.